$CING News

Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma

Roth Capital Reiterates Buy on Cingulate, Lowers Price Target to $9

Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $44

CING: Second Quarter Results

Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Cingulate Q2 EPS $(0.45) Beats $(0.63) Estimate

Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®

Cingulate Joins Russell 3000E Index

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $52

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

Cingulate Receives Complete Response Letter from FDA for CTx-1301

Cingulate Receives FDA Complete Response Letter For ADHD Treatment CTx-1301 Requesting Specific Information About Chemistry, Manufacturing, And Controls, Contains No Concerns Regarding Safety Or Efficacy

HC Wainwright & Co. Reiterates Buy on Cingulate, Maintains $20 Price Target

CING: Building Its Cash Position

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Cingulate Q1 EPS $(0.95) Misses $(0.53) Estimate

Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever